Form 4: Matinas BioPharma Director Edward Neugeboren Acquires Stock Options

Director Edward Neugeboren acquired stock options in Matinas BioPharma Holdings, Inc. subject to stockholder approval of the 2025 Equity Incentive Plan.

Summary

• Edward Neugeboren, a director of Matinas BioPharma Holdings, Inc., reported the acquisition of stock options.
• The transaction occurred on April 30, 2025.
• Neugeboren acquired 11,600 stock options with an exercise price of $0.59.
• These options are subject to the approval of the Issuer's 2025 Equity Incentive Plan, which will be voted on at the Issuer's 2025 annual meeting of stockholders to be held on June 23, 2025.
• 100% of the options vest, subject to stockholder approval of the 2025 Plan, on April 30, 2026.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document simply reports a transaction. The positive or negative impact depends on investor interpretation of the director's confidence and the approval of the equity plan.

Positives

• A director acquiring stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Risks

• The vesting of the options is contingent upon stockholder approval of the 2025 Equity Incentive Plan; failure to obtain this approval would impact the director's compensation.

Future Outlook

The vesting of the options is dependent on future stockholder approval of the 2025 Equity Incentive Plan.

Industry Context

Stock option grants are a common form of executive compensation in the biopharmaceutical industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the pharmaceutical industry.
• The vesting schedule and exercise price would need to be compared to similar grants at peer companies to assess competitiveness.
• Companies like Amgen, Gilead, and Biogen often use stock options as part of their compensation strategy.

Stakeholder Impact

• Shareholders: The transaction could signal confidence from a director, but also dilutes existing shares if options are exercised.
• Employees: The 2025 Equity Incentive Plan may impact employee morale and retention if it provides incentives.

Next Steps

• Stockholder vote on the 2025 Equity Incentive Plan at the annual meeting on June 23, 2025.
• Potential vesting of the options on April 30, 2026, contingent on stockholder approval.

Key Dates

Keywords

stock options, Matinas BioPharma, director, Edward Neugeboren, equity incentive plan, MTNB, beneficial ownership